Best Biotechnology Stocks for 2026
Biotech splits between cash-generative commercial-stage companies and pre-revenue clinical names; Health is unforgiving on cash burn, so runway discipline decides rank.
Biotechnology spans the cash-generative commercial-stage companies and the pre-revenue clinical-stage cohort. Composite scoring is harsh on cash-burning names via the Health pillar (runway, cash to market cap); commercial-stage biotechs surface through the Quality pillar (gross margin, ROIC) and Valuation pillar.
Data as of (updated daily)
Top 20 Biotechnology stocks by composite score
| # | Ticker | Name | Composite |
|---|---|---|---|
| 1 | INCY.US | Incyte Corporation | 83.4 |
| 2 | 688578.SHG | Shanghai Allist Pharmaceuticals Co. Ltd. A | 78.0 |
| 3 | A1SN34.SA | Ascendis Pharma A/S | 75.3 |
| 4 | 002653.SHE | Xizang Haisco Pharmaceutical Group Co Ltd | 73.1 |
| 5 | 688336.SHG | Sunshine Guojian Pharmaceutical Shanghai Co Ltd | 72.8 |
| 6 | ZVRA.US | Zevra Therapeutics Inc. | 72.5 |
| 7 | 1530.HK | 3SBio Inc | 72.0 |
| 8 | 2142.HK | Hbm Holdings Ltd | 71.4 |
| 9 | ALNY.US | Alnylam Pharmaceuticals Inc | 70.4 |
| 10 | INVA.US | Innoviva Inc | 70.1 |
| 11 | EXEL.US | Exelixis Inc | 69.9 |
| 12 | NRIX.US | Nurix Therapeutics Inc | 69.3 |
| 13 | 300871.SHE | Wuhan Hvsen Biotechnology Co Ltd | 69.1 |
| 14 | ACAD.US | ACADIA Pharmaceuticals Inc | 68.8 |
| 15 | AUPH.US | Aurinia Pharmaceuticals Inc | 68.1 |
| 16 | 326030.KO | Sk Biopharmaceuticals Co Ltd | 68.0 |
| 17 | CRMD.US | CorMedix Inc | 67.7 |
| 18 | MGTX.US | MeiraGTx Holdings PLC | 66.6 |
| 19 | 688046.SHG | Gempharmatech Co. Ltd. A | 66.1 |
| 20 | KROS.US | Keros Therapeutics Inc | 65.9 |
Want to drill into Biotechnology stocks?
The full screener applies the Biotechnology industry filter and lets you stack 30+ more filters on top: market cap, country, dividend yield, and the four pillar scores.
Open in screener →Explore related pages
Biotechnology by strategy
Biotechnology by country
Other industries in Healthcare
Parent sector
Recent Biotechnology insights
- Analysis
TSHA Analysis: 78.6% Revenue Growth Offsets -37.3% ROE for $1.51B Biotech
$TSHA revenue surged 78.6%, yet a -37.3% ROE reflects high capital costs during clinical expansion.
- Analysis
Incyte (INCY) Analysis: 30.4% ROE and 15.28 P/E Signal Undervalued Growth
$INCY holds an 81/100 Total Score, placing it in the top tier of nearly 50,000 tracked equities.
- Hidden Gems
CAAS Trades at 4.5x Earnings vs. 35.8x Peer Average
CAAS trades at an ultra-compressed P/E of 4.45 with a 75/100 valuation score, significantly below the peer average of 35.8x, suggesting substantial undervaluation.
- Hidden Gems
Fluor trades at 2.07x earnings with 99.65% ROE, signaling undervaluation.
Fluor (FLR) leads hidden gems with 95/100 valuation score, P/E of 2.02, P/B of 1.18, and ROE of 99.65% signaling deep undervaluation.
- Hidden Gems
CIG Tops Utilities at 88/100 Score, 4.9x Earnings, 23.6% ROE
CIG tops hidden gems at 88/100 valuation score with P/E 4.93 and ROE 23.59%, beating utilities peers for deep value.
Methodology: How we score stocks. Data refreshed nightly around 03:30 ET. This page lists the top 20 by composite score; use the screener for the full ranked list.